Neurocrine Biosciences, Inc. (NBIX) Earnings Call Analysis

NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

Earnings Reports

• Neurocrine Biosciences (NBIX) Q2 2026: Pro Forma Sales Approach $1B as Portfolio Diversifies Beyond Ingreza
  July 31, 2026
• Neurocrine Biosciences (NBIX) Q4 2025: Chronicity Captures 10% CAH Share in First Year, Pipeline Readies for Data Surge
  June 15, 2026
• Neurocrine Biosciences (NBIX) Q1 2026: Ingreza Drives 44% Growth as Chronicity Annualizes Above $600M
  May 06, 2026
• Neurocrine Biosciences (NBIX) Q3 2025: Chronicity Sales Double to $98M as Sales Force Expands 30%
  October 29, 2025
• Neurocrine Biosciences (NBIX) Q2 2025: Krenesiti Revenue Triples, Diversifying Growth Beyond Ingresa
  July 31, 2025
• Neurocrine Biosciences (NBIX) Q1 2025: Chronicity Launch Delivers $15M as Ingresa New Patient Starts Hit Record
  July 07, 2025

Browse all companies